Elicio Therapeutics, Inc.

ELTX Healthcare Biotechnology

In the quarter to June 2026, EPS grew 34.9%, free cash flow grew 8.77% and total debt rose 2.12%, each against the same quarter a year earlier.

1.56 0.22 −12.36%
Market cap
$48.2M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
6/9
Altman Z
0.10
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.29 2.38 2.24 2.77
Net Debt/EBITDA
1.40 1.09 0.53 1.38
Debt/Equity
2.55 5.75 (6.59) 1.20
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.66) (0.44) (0.64) (0.42)
Book value per Share
0.23 0.11 (0.08) 0.41
Free Cash Flow
(11.09) (6.81) (11.64) (8.16)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates